Radiotherapy Combined with Pyrotinib Plus Capecitabine in Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer and Brain Metastases: A Single-Arm, Exploratory Trial

被引：0
|
作者：
Wang, J. [1 ]
Wang, P. [2 ]
You, J. [2 ]
Wang, X. [3 ]
Hou, H. [2 ]
Zhang, B. [2 ]
Chai, Y. [2 ]
Cao, Y. [2 ]
机构：
[1] Tianjin Med Univ Canc Inst & Hosp, Dept Radiat Oncol, Natl Clin Res Ctr Canc, Key Lab Canc Prevent Therapy, Tianjin, Peoples R China
[2] Tianjin Med Univ Canc Inst & Hosp, Dept Radiat Oncol, Natl Clin Res Ctr Canc, Key Lab Canc Prevent Therapy, Tianjin, Peoples R China
[3] Tianjin Med Univ Canc Inst & Hosp, Dept Breast Oncol, Natl Clin Res Ctr Canc, Key Lab Canc Prevent Therapy, Tianjin, Peoples R China
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2024年 / 120卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2625
引用
收藏
页码：E283 / E284
页数：2
相关论文
共 50 条
  • [41] Activating human epidermal growth factor receptor 2 (HER2) gene mutation in bone metastases from breast cancer
    Christgen, Matthias
    Bartels, Stephan
    Luft, Angelina
    Persing, Sascha
    Henkel, Daniel
    Lehmann, Ulrich
    Kreipe, Hans
    VIRCHOWS ARCHIV, 2018, 473 (05) : 577 - 582
  • [42] Activating human epidermal growth factor receptor 2 (HER2) gene mutation in bone metastases from breast cancer
    Matthias Christgen
    Stephan Bartels
    Angelina Luft
    Sascha Persing
    Daniel Henkel
    Ulrich Lehmann
    Hans Kreipe
    Virchows Archiv, 2018, 473 : 577 - 582
  • [43] Molecular alterations and poziotinib, a pan-HER inhibitor efficacy in human epidermal growth factor receptor 2(HER2) positive breast cancers: Combined exploratory biomarker analysis from phase II clinical trial of poziotinib for refractory HER2 positive breast cancer(BC) patients
    Kim, Ji-Yeon
    Lee, Eunjin
    Park, Kyunghee
    Jung, Hae Hyun
    Park, Woong-Yang
    Lee, Kyung-Hun
    Sohn, Joo Hyuk
    Lee, Keun Seok
    Jung, Kyung Hae
    Kim, Jee-Hyun
    Lee, Ki Hyeong
    Im, Seock-Ah
    Park, Yeon Hee
    CANCER RESEARCH, 2018, 78 (04)
  • [44] Pyrotinib Combined with Vinorelbine in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer: A Multicenter, Single-Arm, Prospective Study
    Jiang, Kuikui
    Hong, Ruoxi
    Xia, Wen
    Lu, Qianyi
    Li, Liang
    Huang, Jianhao
    Shi, Yanxia
    Yuan, Zhongyu
    Zheng, Qiufan
    An, Xin
    Xue, Cong
    Huang, Jiajia
    Bi, Xiwen
    Chen, Meiting
    Zhang, Jingmin
    Xu, Fei
    Wang, Shusen
    CANCER RESEARCH AND TREATMENT, 2024, 56 (02): : 513 - 521
  • [45] Neratinib and ado-trastuzumab emtansine for pretreated and untreated human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases: Translational Breast Cancer Research Consortium trial 022
    Freedman, R. A.
    Heiling, H. M.
    Li, T.
    Trapani, D.
    Tayob, N.
    Smith, K. L.
    Davis, R.
    Pereslete, A. M.
    Demeo, M. K.
    Cotter, C.
    Chen, W. Y.
    Parsons, H. A.
    Santa-Maria, C. A.
    Van Poznak, C.
    Moy, B.
    Brufsky, A. M.
    Melisko, M. E.
    o'Sullivan, C. C.
    Ashai, N.
    Rauf, Y.
    Nangia, J. R.
    Burns, R. T.
    Savoie, J.
    Wolff, A. C.
    Winer, E. P.
    Rimawi, M. F.
    Krop, I. E.
    Lin, N. U.
    ANNALS OF ONCOLOGY, 2024, 35 (11) : 993 - 1002
  • [46] Brain Radiotherapy With Pyrotinib and Capecitabine in Patients With ERBB2-Positive Advanced Breast Cancer and Brain MetastasesA Nonrandomized Phase 2 Trial
    Yang, Zhaozhi
    Meng, Jin
    Mei, Xin
    Mo, Miao
    Xiao, Qin
    Han, Xu
    Zhang, Li
    Shi, Wei
    Chen, Xingxing
    Ma, Jinli
    Palmer, Joshua
    Shao, Zhimin
    Zhang, Zhen
    Yu, Xiaoli
    Guo, Xiaomao
    JAMA ONCOLOGY, 2024, 10 (03) : 335 - 341
  • [47] A phase 2 single-arm study to evaluate the clinical activity, safety and tolerability of enzalutamide (ENZA) with trastuzumab in patients with advanced human growth factor receptor 2 (HER2)-positive breast cancer
    Trudeau, Maureen E.
    Winer, Eric
    Steinberg, Joyce L.
    Liosatos, Maggie
    Poondru, Srinivasu
    Dydo, Michael
    Zhou, Yun
    Westphal, Michael
    Peterson, Amy C.
    Gradishar, William
    CANCER RESEARCH, 2015, 75
  • [48] Characteristics of patients with brain metastases from human epidermal growth factor receptor 2-positive breast cancer: subanalysis of Brain Metastases in Breast Cancer Registry
    Laakmann, E.
    Witzel, I
    Neunhoeffer, T.
    Park-Simon, T-W
    Weide, R.
    Riecke, K.
    Polasik, A.
    Schmidt, M.
    Puppe, J.
    Mundhenke, C.
    Lubbe, K.
    Hesse, T.
    Thill, M.
    Zahm, D-M
    Denkert, C.
    Fehm, T.
    Nekljudova, V
    Rey, J.
    Loibl, S.
    Mueller, V
    ESMO OPEN, 2022, 7 (03)
  • [49] Targeting Rac/Cdc42 in human epidermal growth factor receptor 2 (HER2)-positive breast cancer
    Rivera-Robles, M. J.
    Medina-Vlazquez, J. I.
    Borrero-Garcia, L. D.
    Velazquez-Vega, L. E.
    Maldonado, Md M.
    Ruiz-Calderon, J.
    Castillo-Pichardo, L.
    Vivas-Mejia, P.
    Dharmawardhane, S.
    CANCER RESEARCH, 2019, 79 (04)
  • [50] Spotlight on Trastuzumab as Adjuvant Treatment in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer
    Garnock-Jones, Karly P.
    Keating, Gillian M.
    Scott, Lesley J.
    BIODRUGS, 2010, 24 (03) : 207 - 209
12345